Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phosphorus 32

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Phosphorus 32. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-000308-82 Sponsor Protocol Number: oxalate01 Start Date*: 2017-02-08
    Sponsor Name:Universitair Ziekenhuis Brussel
    Full Title: Lanthanum Carbonate (Fosrenol®) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis: a short-term, prospective, open-label, efficacy and safety clinical trial
    Medical condition: Urolithiasis and secondary hyperoxaluria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000171-17 Sponsor Protocol Number: SPD405-207 Start Date*: 2012-10-02
    Sponsor Name:Shire Pharmaceutical Development Ltd.
    Full Title: A Three Part Open-Label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, compare the Efficacy, Safety and Tolerability of 8 weeks treatment with Lanthanum Carbonate and Calcium Carbonat...
    Medical condition: Treatment of Hyperphosphataemia.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) Outside EU/EEA CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-003323-37 Sponsor Protocol Number: MCI-196-E07 Start Date*: 2007-01-29
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorpora...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003324-11 Sponsor Protocol Number: MCI-196-E09 Start Date*: 2007-03-28
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Double-blind, Multi-centre, Randomised, Parallel Group Design, Placebo-controlled, Flexible Dose Study of MCI-196 in Combination with a Calcium-based Phosphate Binder in Chronic Kidney...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) AT (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004888-41 Sponsor Protocol Number: IPeRStudy Start Date*: 2012-12-28
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Intensive Phosphate Control in Development of Renal End Points and Mortality in CKD (the IPeR Study)
    Medical condition: Patients with Chronic Kidney Disease (CKD) not yet on dialysis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002387-33 Sponsor Protocol Number: VitalD Start Date*: 2008-06-03
    Sponsor Name:Hôpital Erasme
    Full Title: Impact of 25-hydroxy vitamin D deficiency and its correction on mineral and bone disorde among hemodialysis patients
    Medical condition: 25-OH vitamin D deficiency and mineral - bone disorder in hemodialysis patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061292 Mineral metabolism disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000298-22 Sponsor Protocol Number: PRENECAL Start Date*: 2012-12-05
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Study to assess the efficacy and safety of oral potassium citrate on the Prevention of nephrocalcinosis in extreme premature: a clinical trial, randomized, double-blind placebo controlled trial. St...
    Medical condition: incidence of nephrocalcinosis in extremely preterm infants
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10029146 Nephrocalcinosis PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004958-18 Sponsor Protocol Number: 20130356 Start Date*: 2014-07-14
    Sponsor Name:Amgen, Inc.
    Full Title: A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
    Medical condition: Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) IT (Completed) HU (Completed) ES (Completed) BE (Completed) CZ (Completed) PT (Completed) DE (Completed) Outside EU/EEA GR (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-001099-14 Sponsor Protocol Number: HIDR-0320/DR Start Date*: 2021-01-12
    Sponsor Name:FAES FARMA S.A.
    Full Title: Randomised, double-blind, double-dummy, multicentre trial to evaluate the efficacy and safety of three different weekly dosages of calcifediol versus placebo in subjects with either vitamin D defic...
    Medical condition: Vitamin D deficiency or insufficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004848 10053828 Blood 1,25-dihydroxy vitamin D decreased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SK (Completed) CZ (Completed) BG (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004558-18 Sponsor Protocol Number: 20000178 Start Date*: 2005-02-11
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism Not Receiving Dialysis
    Medical condition: Secondary Hyperparathyroidism in Chronic Kidney Disease subjects not receiving dialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NO (Ongoing) DK (Completed) IT (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003565-40 Sponsor Protocol Number: PA-CL-03 Start Date*: 2007-12-18
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease ...
    Medical condition: patients with chronic kidney disease undergoing hemodialysis hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-017775-19 Sponsor Protocol Number: CAMN107EIC01 Start Date*: 2010-05-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase
    Medical condition: Newly diagnosed Philadelphia chromosome and/or BCR-ABL positive chronic myeloid leukaemia (CML) in chronic phase in adult patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) HU (Completed) ES (Completed) FI (Completed) GB (Completed) PT (Completed) DE (Completed) SE (Completed) CZ (Completed) DK (Completed) SK (Completed) GR (Completed) AT (Completed) LT (Completed) IT (Completed) LV (Completed) SI (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-002868-14 Sponsor Protocol Number: CLIK066B2201 Start Date*: 2017-04-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 wee...
    Medical condition: change in weight in obese or overweight adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) AT (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002766-20 Sponsor Protocol Number: CAUY922A2101 Start Date*: 2009-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in...
    Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000684-33 Sponsor Protocol Number: OC5-DB-02 Start Date*: 2017-06-06
    Sponsor Name:OxThera Intellectual Property AB
    Full Title: A phase III double-blind, randomized study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020702 Hyperoxalemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001787-23 Sponsor Protocol Number: CSBR759A2201 Start Date*: 2008-08-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week, open label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels i...
    Medical condition: Hyperphosphataemia in patients with Chronic Kidney Disease (CKD) on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) GB (Completed) FI (Completed) SE (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000762-11 Sponsor Protocol Number: 62113-55115 Start Date*: 2014-10-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxoru...
    Medical condition: High Grade Undifferentiated Uterine Sarcoma (HGUS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046821 Uterine sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Ongoing) ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001679-27 Sponsor Protocol Number: 123456 Start Date*: 2016-02-01
    Sponsor Name:CHU-ULg
    Full Title: A PHASE I/II STUDY OF THE COMBINATION OF DEFERASIROX-VITAMIN D AND AZACITIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES (IPSS INT-2 and HIGH).
    Medical condition: MYELODYSPLASTIC SYNDROMES
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003098-17 Sponsor Protocol Number: SOLTI-1402 Start Date*: 2017-03-29
    Sponsor Name:SOLTI
    Full Title: CORALLEEN: A Phase 2 Clinical Trial of multi-agent Chemotherapy or letrozole plus Ribociclib (LEE001) as neoadjuvant treatment for postmenopausal patients with Luminal B/HER2-negative breast cancer.
    Medical condition: Luminal B/HER2-negative breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004096-37 Sponsor Protocol Number: GS-US-174-0108 Start Date*: 2006-05-19
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatiti...
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008910 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) GB (Completed) DE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:41:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA